Quantitative Immunocytochemical Assays of Topoisomerase II in Lung Adenocarcinoma Cell Lines : Correlation to topoisomerase IIα content and topoisomerase II catalytic activity

References

• Berrios M., Osheroff N., Fisher P. A. In situ localization of DNA topoisomerase II a major polypeptide component of the Drosophila nuclear matrix fraction. Proc Natl Acad Sci USA 1985; 82: 4142–6
   PubMed Web of Science ®Google Scholar
• Andoh T. Biological functions of DNA topoisomerases. Jpn J Cancer Chemother 1991; 18: 1543–9, (in Japanese).
   PubMedGoogle Scholar
• Liu L. F. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989; 58: 351–75
   PubMed Web of Science ®Google Scholar
• Drake F. H., Zimmerman J. P., McCabe F. L., et al. Purification of topoisomerase II form amsacrine-resistant P388 leukemia cells. J Biol Chem 1987; 262: 16739–47
   PubMed Web of Science ®Google Scholar
• Chung T. D. Y., Drake F. H., Tan K. B., Per S. R., Crooke S. T., Mirabelli C. K. Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc Natl Acad Sci USA 1989; 86: 9431–5
   PubMed Web of Science ®Google Scholar
• Drake F. H., Hofmann G. A., Bartus H. F., Mattern M. R., Crooke S. T., Mirabelli C. K. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 1989; 28: 8154–60
   PubMed Web of Science ®Google Scholar
• Prosperi E., Sala E., Negri C., et al. Topoisomerase IIα and β in human tumor cell grown in vitro and in vivo. Anticancer Res 1992; 12: 2093–100
   PubMedGoogle Scholar
• Nitiss J. L., Liu Y-X, Harbury P., Jannatipour M., Wasserman R., Wang J. C. Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II. Cancer Res 1992; 52: 4467–72
   PubMed Web of Science ®Google Scholar
• van der Zee A. G. J., de Jong S., Keith W. N., Hollema H., Boonstra H., de Vries E. G. E. Quantitative and qualitative aspects of topoisomerase I and IIα and β in untreated and platinum/cyclophosphamide treated malignant ovarian tumors. Cancer Res 1994; 54: 749–55
   PubMed Web of Science ®Google Scholar
• Takano H., Kohno K., Ono M., Uchida Y., Kuwano M. Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer Res 1991; 51: 3951–7
   PubMed Web of Science ®Google Scholar
• Mirski S. E. L., Evans C. D., Almquist K. C., Slovak M. L., Cole S. P. C. Altered topoisomerase IIα in a drug-resistant small cell lung cancer cell line selected in VP-16. Cancer Res 1993; 53: 4866–73
   PubMedGoogle Scholar
• Matsuo K., Kohno K., Takano H., Sato S., Kiue A., Kuwano M. Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines. Cancer Res 1990; 50: 5819–24
   PubMed Web of Science ®Google Scholar
• Lee M., Wang J. C., Beran M. Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170kDa form of human topoisomerase II. J Mol Biol 1992; 223: 837–43
   PubMed Web of Science ®Google Scholar
• Bugg B. Y., Danks M. K., Beck W. T., Suttle D. P. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Biochemistry 1991; 88: 7654–8
   Google Scholar
• McPherson J. P., Brown G. A., Goldenberg G. J. Characterization of a DNA topoisomerase IIα gene rearrangement in adriamycin-resistant P388 leukemia: Expression of a fusion messenger RNA transcript encoding topoisomerase IIα and the retinoid acid receptor a locus. Cancer Res 1993; 53: 5885–9
   PubMedGoogle Scholar
• Hasegawa T., Isobe K., Nakashima I., Shimokata K. Higher expression of topoisomerase II in lung cancers than normal lung tissues: Different expression pattern from topoisomerase I. Biochem Biophys Res Commun 1993; 195: 409–14
   PubMedGoogle Scholar
• McKenna S. L., Whittaker J. A., Padua R. A., Holmes J. A. Topoisomerase II expression in normal haemopoietic cells and chronic lymphocytic leukemia: Drug sensitivity or resistance. Leukemia 1993; 7: 1199–203
   PubMed Web of Science ®Google Scholar
• Potmesil M., Hsiang Y., Liu L. F., et al. Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. Cancer Res 1988; 48: 3537–43
   PubMed Web of Science ®Google Scholar
• Tandon A. K., Hilsenbeck S. G., Clark G. M., et al. Significance of topoisomerase II in clinical breast cancer. Proc Amer Assoc Cancer Res 1991; 32: 350
   Google Scholar
• van de Zee A. G. J., Hollema H., de Jong S., et al. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary before and after platinum/cyclophosphamide chemotherapy. Cancer Res 1991; 51: 5915–20
   PubMedGoogle Scholar
• Wolverton J. S., Danks M. K., Granzen B., Beck W. T. DNA topoisomerase II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitors. Cancer Res 1992; 52: 4248–53
   PubMedGoogle Scholar
• Efferth T., Mattern J., Volm M. Immunohistochemical detection of P glycoprotein glutathione S transferase and DNA topoisomerase II in human tumors. Oncology 1992; 49: 368–75
   PubMed Web of Science ®Google Scholar
• Kaufmann S. H., McLaughlin S. J., Kastan M. B., Liu L. F., Karp J. E., Burke P. J. Topoisomerase II levels during granulocytic maturation in vitro and in vivo. Cancer Res 1991; 51: 3534–43
   PubMed Web of Science ®Google Scholar
• Volm M., Mattern J. Expression of topoisomerase II, catalase, metallothionein and thymidylate-synthase in human squamous cell lung carcinomas and their correlation with doxorubicin resistance and with patients' smoking habits. Carcinogenesis 1992; 13: 1947–50
   PubMedGoogle Scholar
• Volm M., Kastel M., Mattern J., Efferth T. Expression of resistance factors (P-glycoprotein, glutathione S-transferase-π, and topoisomerase II) and their interrelationship to protooncogene products in renal cell carcinomas. Cancer 1993; 71: 3981–7
   PubMed Web of Science ®Google Scholar
• Tuccari G., Rizzo A., Giuffre G, Barresi G. Immunocytochemical detection of DNA topoisomerase type II in primary breast carcinomas: Correlation with clinico-patholog-ical features. Virchows Archiv A Pathol Anat 1993; 423: 51–5
   Google Scholar
• Heck M. M. S., Earnshaw W. C. Topoisomerase II: A specific marker for cell proliferation. J Cell Biol 1986; 103: 2569–81
   PubMed Web of Science ®Google Scholar
• Isobe H., Miyamoto H., Shimizu T., et al. Prognostic and therapeutic significance of the flow cytometric nuclear DNA content in non-small cell lung cancer. Cancer 1990; 65: 1391–5
   PubMed Web of Science ®Google Scholar
• Deffle A. M., Batra J. K., Goldenberg G. J. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res 1989; 49: 58–62
   PubMedGoogle Scholar
• Kasahara K., Fujiwara Y., Sugimoto Y., et al. Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human cancer cell lines. J Natl Cancer Inst 1992; 84: 113–8
   PubMed Web of Science ®Google Scholar
• Muller M. T., Helal K., Soisson S., Spitzner J. R. A rapid and quantitative micro titer assay for eukaryotic topoisomerase II. Nuc Acid Res 1989; 17: 9499
   PubMedGoogle Scholar
• Carmichael J., DeGraff W. G., Gazdar A. F., Minna J. D., Mitchell J. B. Evaluation of a tetrazolium-based semiautomated colori metric assay: Assessment of chemosensitivity testing. Cancer Res 1987; 47: 936–42
   PubMed Web of Science ®Google Scholar
• Scudiero D. A., Shoemaker R. H., Paull K. D., et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988; 48: 4827–33
   PubMed Web of Science ®Google Scholar
• Negri C., Chiesa R., Cerino A., et al. Monoclonal antibodies to human DNA topoisomerase I and the two isoforms of DNA topoisomerase II: 170- and 180-kDa isozymes. Exp Cell Res 1992; 200: 452–9
   PubMed Web of Science ®Google Scholar
• Zini N., Martelli A. M., Sabatelli P., et al. The 180-kDa isoform of topoisomerase II is localized in the nucleolus and belongs to the structural elements of the nucleolar remnant. Exp Cell Res 1992; 200: 460–6
   PubMedGoogle Scholar
• Heck M. M. S., Hittelman W. N., Earnshaw W. C. Differential expression of DNA topoisomerase I and II during the eukaryotic cell cycle. Proc Natl Acad Sci USA 1988; 85: 1086–90
   PubMed Web of Science ®Google Scholar
• Hsiang Y-H, Wu H-Y, Liu L. F. Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res 1988; 48: 3230–5
   PubMed Web of Science ®Google Scholar
• Feldhoff P. W., Mirski S. E. L., Cole S. P. C., Sullivan D. M. Altered subcellular distribution of topoisomerase IIα in a drug-resistant human small cell lung cancer cell line. Cancer Res 1994; 54: 756–62
   PubMed Web of Science ®Google Scholar